Data-Driven Drug Development – Early Bird for D4 Europe Expires This Week
The early bird rate for our next event D4 (Data-Driven Drug Development) Europe expires this Friday, the only event where attendees will receive data, evidence and case studies from the world’s leading minds in pharma.
This meeting is designed specifically to cater for senior people in pharma, combining strategic insights of value to IT/R&D leaders, with technical, evidence-based use-cases and data that attendees can take away to move forwards with confidence and achieve real development in their organizations today and beyond.
The event will consist of 80-100 senior and C-level delegates, expect audience representation from Roche, Pfizer, Shire, Boehringer Ingelheim, Takenda, Johnson & Johnson, Bayer Healthcare, Janssen, AstraZeneca and many more large and small pharma & biotech companies.
This is the most impressive pharma-focused speaker line-up ever assembled for an event on this topic, on a diverse array of subjects tackling THE critical problems in drug development. You can view the full agenda and line-up of speakers by downloading the event guide here – www.d4-europe.com/download-event-guide
With the Early Bird rate expiring Friday, book your place today and save!
If you’re unable to join us in Basel we are also hosting this meeting in Cambridge, MA later in October. You can find out more about D4 USA by downloading the event guide here – www.d4-pharma.com/event-guide